https://it.gsk.com/it-it/ 2026-03-30T13:37:55.137Z https://it.gsk.com/it-it/azienda/ 2026-03-24T07:31:35Z https://it.gsk.com/it-it/azienda/scopo-strategia-e-cultura/ 2026-03-25T16:58:55.567Z https://it.gsk.com/it-it/azienda/gsk-in-italia/ 2026-03-25T16:51:32.323Z https://it.gsk.com/it-it/azienda/gsk-in-italia/le-nostre-sedi/ 2026-01-15T14:49:00.163Z https://it.gsk.com/it-it/azienda/gsk-in-italia/la-nostra-storia/ 2025-08-08T18:12:42.973Z https://it.gsk.com/it-it/azienda/gsk-in-italia/organizzazione-locale/ 2026-03-18T09:40:19.603Z https://it.gsk.com/it-it/azienda/policy/ 2026-03-30T14:05:26.46Z https://it.gsk.com/it-it/innovazione/ 2026-03-25T16:38:01.33Z https://it.gsk.com/it-it/innovazione/aree-terapeutiche/ 2025-08-08T18:12:29.837Z https://it.gsk.com/it-it/innovazione/gli-studi-clinici/ 2026-01-15T15:16:13.417Z https://it.gsk.com/it-it/innovazione/gli-studi-clinici/studi-osservazionali-informazioni-e-tutela-dei-pazienti/ 2026-02-25T12:01:35.967Z https://it.gsk.com/it-it/innovazione/il-sostegno-alle-proposte-di-ricerca-indipendente-iss/ 2026-01-15T15:20:39.003Z https://it.gsk.com/it-it/prodotti/ 2025-08-08T18:12:15.323Z https://it.gsk.com/it-it/prodotti/i-nostri-prodotti-in-ordine-alfabetico/ 2026-01-22T12:08:34.38Z https://it.gsk.com/it-it/prodotti/le-patologie-di-cui-ci-occupiamo/ 2025-08-08T18:12:19.743Z https://it.gsk.com/it-it/prodotti/le-risposte-sui-prodotti-gsk/ 2026-01-22T12:16:18.673Z https://it.gsk.com/it-it/prodotti/la-farmacovigilanza/ 2025-08-08T18:12:20.723Z https://it.gsk.com/it-it/responsabilita/ 2026-01-22T12:21:33.32Z https://it.gsk.com/it-it/responsabilita/inclusione/ 2026-01-07T16:20:15.81Z https://it.gsk.com/it-it/responsabilita/standard-etici/ 2026-01-22T12:29:14.39Z https://it.gsk.com/it-it/responsabilita/standard-etici/la-collaborazione-con-gli-operatori-sanitari/ 2026-01-22T12:35:50.193Z https://it.gsk.com/it-it/responsabilita/standard-etici/efpia-disclosure/ 2025-08-08T18:11:51.893Z https://it.gsk.com/it-it/responsabilita/standard-etici/la-collaborazione-con-le-associazioni-di-pazienti/ 2026-01-22T12:39:29.247Z https://it.gsk.com/it-it/responsabilita/il-volontariato-d-impresa/ 2026-01-22T12:41:38.213Z https://it.gsk.com/it-it/responsabilita/il-siena-vaccines-science-centre/ 2025-08-08T18:12:13.557Z https://it.gsk.com/it-it/responsabilita/le-campagne-di-sensibilizzazione/ 2026-01-27T08:49:13.873Z https://it.gsk.com/it-it/responsabilita/leggere-per-crescere/ 2025-08-12T11:20:30.937Z https://it.gsk.com/it-it/responsabilita/leggere-per-crescere/le-news-di-leggere-per-crescere/ 2025-08-11T16:25:51.223Z https://it.gsk.com/it-it/media/ 2026-01-22T12:59:23.223Z https://it.gsk.com/it-it/media/comunicati-stampa/ 2025-08-15T10:18:59.9Z https://it.gsk.com/it-it/media/comunicati-stampa/hiv-da-parma-innovazione-industria-e-cure-per-i-pazienti-di-tutto-il-mondo/ 2025-08-08T18:05:14.39Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-un-azienda-moderna-non-puo-fare-a-meno-di-diversita-e-inclusione/ 2025-08-08T18:05:10.327Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-ancora-prima-nell-access-to-medicine-index/ 2025-08-08T18:05:08.443Z https://it.gsk.com/it-it/media/comunicati-stampa/lupus-adesso-basta-un-iniezione-alla-settimana/ 2025-08-08T18:05:07.833Z https://it.gsk.com/it-it/media/comunicati-stampa/i-rapporti-di-gsk-con-gli-operatori-e-le-organizzazioni-sanitarie/ 2025-08-08T18:05:07.14Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-completa-lacquisizione-di-tesaro-unazienda-biofarmaceutica-focalizzata-sulloncologia-1/ 2025-08-08T18:05:03.193Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-merck-kgaa-darmstadt-germania-annunciano-unalleanza-globale/ 2025-08-08T18:05:01.607Z https://it.gsk.com/it-it/media/comunicati-stampa/i-dati-dello-studio-garnet-indicano-una-robusta-attivita-di-dostarlimab-in-pazienti-con-carcinoma-endometriale-avanzato-o-ricorrente/ 2025-08-08T18:05:00.887Z https://it.gsk.com/it-it/media/comunicati-stampa/per-la-terapia-della-bpco-vale-la-regola-del-tre-in-uno/ 2025-08-08T18:04:59.037Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-21-03-2019/ 2025-08-08T18:04:57.217Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-del-28-marzo-2019/ 2025-08-08T18:04:56.533Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-02-05-2019/ 2025-08-08T18:04:55.893Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-15-giugno-2019/ 2025-08-08T18:04:53.923Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-del-24-09-2019/ 2025-08-08T18:04:52.08Z https://it.gsk.com/it-it/media/comunicati-stampa/lo-studio-prima-di-fase-3-su-niraparib-e-il-primo-studio-a-dimostrare-che-un-inibitore-parp-migliora-significativamente-la-pfs/ 2025-08-08T18:04:51.38Z https://it.gsk.com/it-it/media/comunicati-stampa/sindrome-ipereosinofila-mepolizumab-e-il-primo-farmaco-a-ridurre-le-riacutizzazioni/ 2025-08-08T18:04:49.193Z https://it.gsk.com/it-it/media/comunicati-stampa/lo-studio-registrativo-dreamm-2-ha-dimostrato-un-tasso-di-risposta-globale-clinicamente-significativo/ 2025-08-08T18:04:47.11Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-affida-la-licenza-del-candidato-vaccino-per-la-tubercolosi-al-bill-melinda-gates-medical-research-institute-per-la-prosecuzione-dello-sviluppo/ 2025-08-08T18:04:46.307Z https://it.gsk.com/it-it/media/comunicati-stampa/dottorato-ad-honorem-per-rino-rappuoli/ 2025-08-08T18:04:45.667Z https://it.gsk.com/it-it/media/comunicati-stampa/mieloma-multiplo-recidivante-e-refrattario-l-ema-valutera-l-immissione-accelerata-in-commercio-di-belantamab-mafodotin/ 2025-08-08T18:04:43.85Z https://it.gsk.com/it-it/media/comunicati-stampa/cepi-e-gsk-annunciano-una-collaborazione/ 2025-08-08T18:04:41.97Z https://it.gsk.com/it-it/media/comunicati-stampa/ema-ha-convalidato-la-sottomissione-della-richiesta-per-la-maa-di-niraparib/ 2025-08-08T18:04:39.78Z https://it.gsk.com/it-it/media/comunicati-stampa/aiutiamoglieroi-e-il-progetto-di-gsk-italia-e-dei-suoi-dipendenti-per-affrontare-l-emergenza-covid19/ 2025-08-08T18:04:36.267Z https://it.gsk.com/it-it/media/comunicati-stampa/mepolizumab-studio-synapse/ 2025-08-08T18:04:35.483Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-si-alleano-per-individuare-nuove-soluzioni-contro-il-coronavirus/ 2025-08-08T18:04:34.69Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-e-gsk-collaborazione-vaccinale-per-combattere-covid-19/ 2025-08-08T18:04:33.557Z https://it.gsk.com/it-it/media/comunicati-stampa/noi-per-t-r-e-gsk-per-le-pazienti-i-loro-familiari-e-gli-operatori-sanitari-che-ogni-giorno-sfidano-i-tumori-ginecologici/ 2025-08-08T18:04:30.773Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-lintenzione-di-produrre-1-miliardo-di-dosi-di-adiuvante/ 2025-08-08T18:04:30.163Z https://it.gsk.com/it-it/media/comunicati-stampa/studi-dreamm-2-e-dreamm-6-belantamab-mafodotin-mieloma-multiplo/ 2025-08-08T18:04:29.553Z https://it.gsk.com/it-it/media/comunicati-stampa/fabio-landazabal-alla-guida-di-gsk-pharma-in-italia/ 2025-08-08T18:04:28.733Z https://it.gsk.com/it-it/media/comunicati-stampa/aggiornamento-della-schedula-vaccinale-europea-per-il-vaccino-contro-il-meningococco-b-a-4-componenti/ 2025-08-08T18:04:28.15Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-investe-in-innovazione-a-siena-nuovo-trd-smart-lab/ 2025-08-08T18:04:25.12Z https://it.gsk.com/it-it/media/comunicati-stampa/fabio-landazabal-nel-comitato-di-presidenza-di-farmindustria/ 2025-08-08T18:04:23.78Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-medicago-collaborazione-per-candidato-vaccino-adiuvato-covid-19/ 2025-08-08T18:04:23.05Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-curevac-annunciano-una-collaborazione-strategica-usando-la-tecnologia-mrna/ 2025-08-08T18:04:22.377Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-del-chmp-su-belantamab-mafodotin-per-il-trattamento-del-mieloma-multiplo-recidivato-e-refrattario/ 2025-08-08T18:04:21.517Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-europea-belantamab-mafodotin/ 2025-08-08T18:04:19.793Z https://it.gsk.com/it-it/media/comunicati-stampa/terapia-domiciliare-per-l-asma-severo-eosinofilo/ 2025-08-08T18:04:17.41Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-gsk-accordo-con-unione-europea-vaccino-covid-19/ 2025-08-08T18:04:16.81Z https://it.gsk.com/it-it/media/comunicati-stampa/positive-opinion-chmp-niraparib-1l-carcinoma-ovarico/ 2025-08-08T18:04:16.12Z https://it.gsk.com/it-it/media/comunicati-stampa/formazione-e-innovazione-nello-stabilimento-gsk-di-parma/ 2025-08-08T18:04:15.497Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-biotechnology-e-gsk-annunciano-l-espansione-globale-alla-fase-3-dello-studio-comet-ice-che-valuta-vir-7831-per-il-trattamento-di-covid-19/ 2025-08-08T18:04:14.847Z https://it.gsk.com/it-it/media/comunicati-stampa/indagine-sulle-richieste-delle-persone-con-hiv-in-italia/ 2025-08-08T18:04:13.61Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-presenta-i-dati-clinici-candidati-vaccini-rsv/ 2025-08-08T18:04:10.7Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-e-gsk-supporteranno-covax-con-200-milioni-di-dosi-di-vaccino-covid-19/ 2025-08-08T18:04:09.287Z https://it.gsk.com/it-it/media/comunicati-stampa/la-commissione-europea-approva-niraparib/ 2025-08-08T18:04:08.66Z https://it.gsk.com/it-it/media/comunicati-stampa/nuovi-obiettivi-ambientali-per-gsk/ 2025-08-08T18:04:08.023Z https://it.gsk.com/it-it/media/comunicati-stampa/i-progressi-di-belantamab-mafodotin-al-congresso-ash/ 2025-08-08T18:04:05.193Z https://it.gsk.com/it-it/media/comunicati-stampa/medicago-e-gsk-partenza-studi-clinici-di-fase-23-candidato-vaccino-adiuvato-covid-19/ 2025-08-08T18:04:04.55Z https://it.gsk.com/it-it/media/comunicati-stampa/studio-di-fase-3-su-candidato-vaccino-rsv-donne-in-gravidanza/ 2025-08-08T18:04:03.977Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-e-gsk-annunciano-un-ritardo-nel-loro-programma-di-vaccino-covid-19/ 2025-08-08T18:04:03.367Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-biotechnology-e-gsk-annunciano-linizio-dello-studio-activ-3/ 2025-08-08T18:04:02.75Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-continua-ad-investire-a-rosia-con-18-milioni-di-euro-per-nuove-tecnologie-e-processi-produttivi/ 2025-08-08T18:04:01.94Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-biotechnology-e-gsk-annunciano-studio-per-trattamento-precoce-covid-19/ 2025-08-08T18:03:58.17Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-si-conferma-prima-nellaccess-to-medicine-index/ 2025-08-08T18:03:57.227Z https://it.gsk.com/it-it/media/comunicati-stampa/lilly-vir-biotechnology-e-gsk-annunciano-il-primo-paziente-dello-studio-blaze-4-in-trattamento-per-covid-19/ 2025-08-08T18:03:56.583Z https://it.gsk.com/it-it/media/comunicati-stampa/collaborazione-gsk-curevac-vaccini-mrna-contro-covid-19/ 2025-08-08T18:03:55.947Z https://it.gsk.com/it-it/media/comunicati-stampa/avvio-studi-clinici-fase-iii-candidato-vaccino-rsv/ 2025-08-08T18:03:55.277Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-espansione-collaborazione-per-terapie-influenza-e-virus-respiratori/ 2025-08-08T18:03:52.28Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-sanofi-studio-fase-2-candato-vaccino-contro-covid-19/ 2025-08-08T18:03:51.66Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-per-i-pazienti-patient-support-programme/ 2025-08-08T18:03:51.013Z https://it.gsk.com/it-it/media/comunicati-stampa/presentati-i-risultati-dellanticorpo-monoclonale-di-gsk-otilimab/ 2025-08-08T18:03:50.39Z https://it.gsk.com/it-it/media/comunicati-stampa/chmp-raccomanda-approvazione-di-dostarlimab-per-il-carcinoma-endometriale-ricorrente-o-avanzato/ 2025-08-08T18:03:49.7Z https://it.gsk.com/it-it/media/comunicati-stampa/importante-finanziamento-a-gvgh-da-carb-x-per-lotta-antimicrobicoresistenza/ 2025-08-08T18:03:48.937Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-7831-riduce-lospedalizzazione-e-il-rischio-di-morte-nel-trattamento-precoce-degli-adulti-con-covid-19/ 2025-08-08T18:03:45.217Z https://it.gsk.com/it-it/media/comunicati-stampa/medicago-e-gsk-iniziano-fase-3-vaccino-adiuvato-covid-19/ 2025-08-08T18:03:44.323Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-avvia-il-primo-studio-di-fase-3-a-per-i-pazienti-con-asma-grave/ 2025-08-08T18:03:43.443Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-richiesta-di-autorizzazione-alluso-di-emergenza-alla-fda-per-vir-7831/ 2025-08-08T18:03:42.283Z https://it.gsk.com/it-it/media/comunicati-stampa/lilly-vir-biotechnology-e-gsk-annunciano-dati-studio-di-fase-2-blaze-4-contro-covid-19/ 2025-08-08T18:03:37.917Z https://it.gsk.com/it-it/media/comunicati-stampa/arriva-in-italia-il-primo-trattamento-per-l-asma-grave-eosinofilico-refrattario-nei-bambini/ 2025-08-08T18:03:37.15Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-italia-e-una-health-friendly-company-un-ulteriore-traguardo-come-modern-employer/ 2025-08-08T18:03:36.28Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-continuano-le-discussioni-con-gli-enti-regolatori-per-rendere-disponibile-vir-7831-contro-covid-19/ 2025-08-08T18:03:35.587Z https://it.gsk.com/it-it/media/comunicati-stampa/al-via-la-prevenzionenonhaetait/ 2025-08-08T18:03:34.937Z https://it.gsk.com/it-it/media/comunicati-stampa/la-commissione-europea-approva-dostarlimab/ 2025-08-08T18:03:33.863Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-prima-farmaceutica-nella-classifica-linkedin/ 2025-08-08T18:03:31.597Z https://it.gsk.com/it-it/media/comunicati-stampa/arriva-in-italia-nuovo-vaccino-ricombinante-adiuvato-contro-herpes-zoster/ 2025-08-08T18:03:30.88Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-ce-belimumab-per-pazienti-adulti-con-nefrite-lupica-attiva/ 2025-08-08T18:03:30.25Z https://it.gsk.com/it-it/media/comunicati-stampa/il-candidato-vaccino-sanofi-e-gsk-covid-19-dimostra-una-forte-risposta-immunitaria/ 2025-08-08T18:03:29.58Z https://it.gsk.com/it-it/media/comunicati-stampa/medicago-e-gsk-annunciano-risultati-intermedi-positivi-per-candidato-vaccino-covid-19-adiuvato/ 2025-08-08T18:03:28.093Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-ema-su-sotrovimab-di-gsk-e-vir-biotechnology-per-il-trattamento-precoce-di-covid-19/ 2025-08-08T18:03:25.557Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-autorizzazione-per-luso-di-emergenza-di-sotrovimab-vir-7831-dalla-fda-statunitense/ 2025-08-08T18:03:24.89Z https://it.gsk.com/it-it/media/comunicati-stampa/bpco-la-combinazione-ottimale-farmacodispositivo/ 2025-08-08T18:03:24.113Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-rosia-inaugura-la-nuova-area-dedicata-alla-formazione/ 2025-08-08T18:03:23.44Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-accordoappalto-congiunto-con-la-ce-per-sotrovimab/ 2025-08-08T18:03:22.617Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-presenta-a-esmo-i-progressi-della-pipeline-oncologica/ 2025-08-08T18:03:18.883Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-chmp-approvazione-mepolizumab-in-tre-ulteriori-malattie/ 2025-08-08T18:03:18.333Z https://it.gsk.com/it-it/media/comunicati-stampa/oms-raccomanda-vaccino-gsk-contro-la-malaria/ 2025-08-08T18:03:17.73Z https://it.gsk.com/it-it/media/comunicati-stampa/studio-somministrazione-intramuscolare-di-sotrovimab-per-il-trattamento-precoce-di-covid-19-raggiunge-endpoint-primario/ 2025-08-08T18:03:17.153Z https://it.gsk.com/it-it/media/comunicati-stampa/mepolizumab-approvato-dalla-commissione-europea-in-tre-ulteriori-malattie-causate-da-eosinofili/ 2025-08-08T18:03:16.45Z https://it.gsk.com/it-it/media/comunicati-stampa/un-missile-teleguidato-contro-il-mieloma-multiplo/ 2025-08-08T18:03:15.583Z https://it.gsk.com/it-it/media/comunicati-stampa/i-dati-preclinici-dimostrano-che-sotrovimab-mantiene-lattivita-contro-le-mutazioni-chiave-di-omicron/ 2025-08-08T18:03:11.783Z https://it.gsk.com/it-it/media/comunicati-stampa/niraparib-disponibile-come-trattamento-di-mantenimento-in-prima-linea-del-carcinoma-ovarico-avanzato/ 2025-08-08T18:03:10.973Z https://it.gsk.com/it-it/media/comunicati-stampa/sotrovimab-mantiene-lattivita-contro-lintera-combinazione-di-mutazioni-nella-proteina-spike-della-variante-omicron-sars-cov-2/ 2025-08-08T18:03:10.223Z https://it.gsk.com/it-it/media/comunicati-stampa/ash-2021-nuovi-dati-di-belantamab-mafodotin-nel-trattamento-del-mieloma-multiplo/ 2025-08-08T18:03:09.573Z https://it.gsk.com/it-it/media/comunicati-stampa/sotrovimab-ha-ottenuto-lautorizzazione-dalla-commissione-europea-per-il-trattamento-precoce-del-covid-19/ 2025-08-08T18:03:05.76Z https://it.gsk.com/it-it/media/comunicati-stampa/arriva-app-vik-tumore-ovarico/ 2025-08-08T18:03:05Z https://it.gsk.com/it-it/media/comunicati-stampa/i-giovani-e-la-sfida-all-hiv-progetto-d-informazione-per-le-scuole-superiori/ 2025-08-08T18:03:04.39Z https://it.gsk.com/it-it/media/comunicati-stampa/haleon-la-nuova-azienda-che-nascera-dallo-spin-off-della-divisione-consumer-healthcare-gsk/ 2025-08-08T18:03:03.68Z https://it.gsk.com/it-it/media/comunicati-stampa/herpes-zoster-piu-del-90-degli-over-50-ha-gia-contratto-il-virus-ma-solo-il-7-si-sente-a-rischio/ 2025-08-08T18:03:02.927Z https://it.gsk.com/it-it/media/comunicati-stampa/belimumab-nefrite-lupica/ 2025-08-08T18:02:58.577Z https://it.gsk.com/it-it/media/comunicati-stampa/allasma-non-lasciare-la-prima-mossa-gioca-danticipo/ 2025-08-08T18:02:57.863Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-ovarico-con-niraparib-triplicata-la-sopravvivenza-libera-da-malattia/ 2025-08-08T18:02:57.06Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-dati-di-fase-iii-vaccino-rsv-negli-anziani/ 2025-08-08T18:02:56.38Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-un-investimento-di-1-miliardo-di-sterline-in-ricerca-e-sviluppo-in-10-anni-per-le-malattie-infettive-nei-pvs/ 2025-08-08T18:02:55.3Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-investe-in-innovazione-inaugurato-a-siena-il-nuovo-trd-smart-lab/ 2025-08-08T18:02:52.95Z https://it.gsk.com/it-it/media/comunicati-stampa/prevenzione-e-innovazione-per-la-salute-del-futuro/ 2025-08-08T18:02:52.317Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-in-italia-disponibile-dostarlimab-la-prima-immunoterapia-su-misura-per-le-pazienti-con-malattia-ricorrente-e-avanzata/ 2025-08-08T18:02:51.68Z https://it.gsk.com/it-it/media/comunicati-stampa/bpco-l-efficacia-delle-terapie-gsk-per-i-pazienti-aumentano-la-funzionalita-polmonare-e-diminuiscono-le-riacutizzazioni/ 2025-08-08T18:02:50.92Z https://it.gsk.com/it-it/media/comunicati-stampa/niraparib-mostra-un-beneficio-duraturo-in-termini-di-sopravvivenza/ 2025-08-08T18:02:50.27Z https://it.gsk.com/it-it/media/comunicati-stampa/loms-concede-la-prequalifica-a-mosquirix-di-gsk-il-primo-e-unico-vaccino-contro-la-malaria-approvato-al-mondo/ 2025-08-08T18:02:46.417Z https://it.gsk.com/it-it/media/comunicati-stampa/tic-toc-la-gentilezza-del-tempo-una-web-series-per-raccontare-il-mieloma-multiplo/ 2025-08-08T18:02:45.583Z https://it.gsk.com/it-it/media/comunicati-stampa/evidenze-sul-candidato-vaccino-contro-il-virus-respiratorio-sinciziale-rsv-di-gsk/ 2025-08-08T18:02:44.45Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-una-collaborazione-ampliata-con-tempus-nella-medicina-di-precisione-per-accelerare-la-ricerca-e-lo-sviluppo/ 2025-08-08T18:02:39.963Z https://it.gsk.com/it-it/media/comunicati-stampa/nuovi-dati-sul-vaccino-ricombinante-contro-l-herpes-zoster/ 2025-08-08T18:02:39.267Z https://it.gsk.com/it-it/media/comunicati-stampa/un-diario-di-bordo-per-non-perdere-di-vista-la-bpco/ 2025-08-08T18:02:38.61Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-in-testa-all-access-to-medicine-index/ 2025-08-08T18:02:37.92Z https://it.gsk.com/it-it/media/comunicati-stampa/presentati-allash-nuovi-dati-per-i-pazienti-affetti-da-mielofibrosi-trattati-con-momelotinib/ 2025-08-08T18:02:35.973Z https://it.gsk.com/it-it/media/comunicati-stampa/lupus-parola-d-ordine-proteggere-i-reni/ 2025-08-08T18:02:33.313Z https://it.gsk.com/it-it/media/comunicati-stampa/new-england-journal-of-medicine-rafforza-il-potenziale-del-candidato-vaccino-gsk-per-la-prevenzione-del-virus-respiratorio-sinciziale-negli-adulti-anziani/ 2025-08-08T18:02:32.59Z https://it.gsk.com/it-it/media/comunicati-stampa/shingle-awareness-week-solo-un-intervistato-su-due-consapevole-della-gravita-dell-herpes-zoster/ 2025-08-08T18:02:31.9Z https://it.gsk.com/it-it/media/comunicati-stampa/una-webserie-per-raccontare-i-tumori-dell-ovaio-e-dell-endometrio/ 2025-08-08T18:02:31.26Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-dati-positivi-per-il-candidato-vaccino-meningococcico-5-in-1-abcwy/ 2025-08-08T18:02:30.633Z https://it.gsk.com/it-it/media/comunicati-stampa/gvgh-15-anni-dedicati-alla-salute-globale/ 2025-08-08T18:02:25.883Z https://it.gsk.com/it-it/media/comunicati-stampa/covid-trattamento-precoce-dei-fragili-anticorpi-monoclonali-ancora-efficaci/ 2025-08-08T18:02:24.657Z https://it.gsk.com/it-it/media/comunicati-stampa/terapia-di-precisione-per-le-malattie-eosinofile-si-fa-in-quattro/ 2025-08-08T18:02:22.103Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-del-chmp-per-il-candidato-vaccino-per-gli-adulti-anziani-contro-il-virus-respiratorio-sinciziale-di-gsk/ 2025-08-08T18:02:21.293Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-italia-piu-tempo-per-i-momenti-che-contano/ 2025-08-08T18:02:20.677Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-condivide-dati-positivi-sul-suo-vaccino-per-adulti-piu-anziani-contro-il-virus-respiratorio-sinciziale-rsv/ 2025-08-08T18:02:19.887Z https://it.gsk.com/it-it/media/comunicati-stampa/nuovi-dati-efficacia-del-vaccino-gsk-nella-prevenzione-dell-herpes-zoster/ 2025-08-08T18:02:18.75Z https://it.gsk.com/it-it/media/comunicati-stampa/giornata-mondiale-contro-la-meningite-i-risultati-di-una-survey-internazionale-di-ipsos/ 2025-08-08T18:02:07.557Z https://it.gsk.com/it-it/media/comunicati-stampa/via-libera-ue-allutilizzo-in-prima-linea-di-dostarlimab-in-combinazione-con-la-chemioterapia-nel-cancro-dellendometrio/ 2025-08-08T18:02:06.08Z https://it.gsk.com/it-it/media/comunicati-stampa/mieloma-multiplo-la-combinazione-belantamab-bortexomib-e-desametasone-aumenta-la-sopravvivenza-libera-da-malattia/ 2025-08-08T18:02:04.843Z https://it.gsk.com/it-it/media/comunicati-stampa/global-health-e-salute-per-il-futuro-la-via-della-prevenzione-20/ 2025-08-08T18:02:02.343Z https://it.gsk.com/it-it/media/comunicati-stampa/mielofibrosi-via-libera-della-commissione-europea-a-momelotinib/ 2025-08-08T18:02:01.63Z https://it.gsk.com/it-it/media/comunicati-stampa/dreamm-7-la-combinazione-con-belantamab-mafodotin-ha-quasi-triplicato-la-sopravvivenza-media-libera-da-progressione/ 2025-08-08T18:02:00.843Z https://it.gsk.com/it-it/media/comunicati-stampa/lo-studio-ruby-mostra-il-potenziale-delle-combinazioni-di-dostarlimab/ 2025-08-08T18:01:59.163Z https://it.gsk.com/it-it/media/comunicati-stampa/vax-corner-online-il-nuovo-portale-sulle-vaccinazioni-per-gli-operatori-sanitari/ 2025-08-08T18:01:56.333Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-chmp-per-vaccino-contro-il-rsv/ 2025-08-08T18:01:55.687Z https://it.gsk.com/it-it/media/comunicati-stampa/la-commissione-europea-approva-lindicazione-di-eta-estesa-per-arexvy/ 2025-08-08T18:01:54.953Z https://it.gsk.com/it-it/media/comunicati-stampa/ultimi-dati-su-depemokimab-ad-ers-2024/ 2025-08-08T18:01:53.123Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-presenta-dati-positivi-per-il-vaccino-contro-rsv/ 2025-08-08T18:01:49.487Z https://it.gsk.com/it-it/media/comunicati-stampa/io-ema-e-tu-una-piazza-virtuale-per-conoscere-i-tumori-del-sangue/ 2025-08-08T18:01:48.72Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-gsk-italia-del-10112024/ 2025-08-08T18:01:47.943Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-gsk-italia-11122024/ 2025-08-08T18:01:47.287Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-via-libera-della-commissione-europea-all-utilizzo-di-dostarlimab-piu-chemioterapia/ 2025-08-08T18:01:46.403Z https://it.gsk.com/it-it/media/comunicati-stampa/momelotinib-una-nuova-terapia-per-la-mielofibrosi/ 2025-08-08T18:01:42.65Z https://it.gsk.com/it-it/media/comunicati-stampa/fuoco-di-sant-antonio-non-facciamo-gli-struzzi/ 2025-08-08T18:01:41.81Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-via-libera-in-prima-linea-alla-combinazione-immunoterapia-e-chemioterapia/ 2025-08-08T18:01:41.07Z https://it.gsk.com/it-it/media/comunicati-stampa/mieloma-multiplo-triplicata-sopravvivenza-libera-da-progressione-con-una-terapia-a-tre-farmaci/ 2025-08-08T18:01:40.07Z https://it.gsk.com/it-it/media/comunicati-stampa/approvate-dallue-nuove-combinazioni-con-belentamab-mafodotin/ 2025-08-08T18:01:36.297Z https://it.gsk.com/it-it/media/comunicati-stampa/presente-e-futuro-della-copd-stability/ 2025-10-09T12:37:07.173Z https://it.gsk.com/it-it/media/comunicati-stampa/studio-italiano-dimostra-il-ripristino-delle-alterazioni-del-tessuto-nasale-in-rinosinusite-cronica-con-poliposi-nasale-con-lanticorpo-monoclonale-anti-interleuchina-5-il-5/ 2025-10-29T11:20:20.553Z https://it.gsk.com/it-it/media/comunicati-stampa/incontro-con-il-nuovo-general-manager-di-gsk-italia/ 2025-11-03T13:37:54.713Z https://it.gsk.com/it-it/media/comunicati-stampa/bpco-la-malattia-invisibile-che-si-sente-l-impatto-su-pazienti-famiglie-e-sanita-pubblica/ 2025-11-11T11:51:04.453Z https://it.gsk.com/it-it/media/comunicati-stampa/il-vaccino-contro-il-virus-respiratorio-sinciziale-rsv-di-gsk-ottiene-lapprovazione-europea-per-lestensione-dell-utilizzo-in-tutti-gli-adulti-dai-18-anni-in-su/ 2026-01-26T16:39:21.113Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-ema-mepolizumab-in-bpco/ 2026-02-06T11:31:02.243Z https://it.gsk.com/it-it/media/comunicati-stampa/progetto-di-ascolto-sui-pazienti-con-lupus-appena-pubblicato-sul-journal-of-clinical-medicine/ 2026-02-11T13:00:07.363Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-ema-depemokimab-asma-grave-e-rinosinusite-cronica-con-poliposi-nasale/ 2026-02-17T11:31:50.93Z https://it.gsk.com/it-it/media/comunicati-stampa/il-vaccino-antirsv-di-gsk-associato-a-riduzioni-di-alcuni-rischi-legati-al-virus-tra-cui-infarto-ictus-e-gravi-riacutizzazioni-di-bpco-e-asma-a-dimostrarlo-uno-studio-real-world/ 2026-02-18T11:13:40.29Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-aifa-approva-l-estensione-dell-immunoterapia-con-dostarlimab/ 2026-02-24T09:04:16.84Z https://it.gsk.com/it-it/media/media-contacts/ 2026-03-30T13:16:33.683Z https://it.gsk.com/it-it/media/rss/ 2025-08-11T16:32:32.56Z https://it.gsk.com/it-it/lavora-con-noi/ 2026-01-07T16:12:59.117Z https://it.gsk.com/it-it/lavora-con-noi/lavorare-in-gsk/ 2026-03-30T13:27:07.333Z https://it.gsk.com/it-it/lavora-con-noi/lavorare-in-gsk/lo-smart-working-in-gsk/ 2025-08-08T18:01:26.687Z https://it.gsk.com/it-it/lavora-con-noi/candidati-con-esperienza/ 2025-08-08T18:01:27.46Z https://it.gsk.com/it-it/lavora-con-noi/studenti-e-neolaureati/ 2025-12-08T19:48:22.997Z https://it.gsk.com/it-it/lavora-con-noi/le-posizioni-aperte-in-italia/ 2025-08-15T10:23:31.96Z https://it.gsk.com/it-it/contattaci/ 2026-03-30T13:40:42.697Z https://it.gsk.com/it-it/contattaci/fornitori/ 2026-03-30T13:59:28.043Z https://it.gsk.com/it-it/condizioni-per-lutilizzo/ 2026-03-30T13:52:00.093Z https://it.gsk.com/it-it/accessibilita/ 2025-09-23T11:01:06.033Z https://it.gsk.com/it-it/accessibilita/report-accessibilita/ 2025-09-23T11:22:18.043Z https://it.gsk.com/it-it/cookie-policy/ 2025-08-08T18:11:36.363Z https://it.gsk.com/it-it/informativa-sulla-privacy/ 2025-08-08T18:11:34.487Z https://it.gsk.com/it-it/dove-siamo/ 2025-08-11T14:50:53.607Z https://it.gsk.com/it-it/cerca-in-gsk/ 2025-08-08T18:12:53.637Z https://it.gsk.com/it-it/sitemap/ 2025-08-15T10:52:09.863Z https://it.gsk.com/it-it/errore-404/ 2025-08-11T14:20:52.377Z